KZR-616
KZR-616 has been studied in 1 paper since 2025: none in people yet, 1 review. No study of it in people or animals has been published yet. The newest paper, Oct 12, 2025: “Immunoproteasomes in Skeletal Muscle Pathologies: Emerging Roles, Conflicting Evidence, and Future Directions”.
1 paper studies it1 findingUpdated
What did studies of KZR-616 find?
1Studies of KZR-616 measured 1 outcome; the most studied are inflammation (1 study).
Inflammation
downin reviews1
1 study
Inflammation
downin reviews1
KZR-616 inhibits inflammation in preclinical models of autoimmune myositis and muscle atrophy.
“Selective IMP inhibitors, such as ONX 0914 and KZR-616, display potent anti-inflammatory effects in preclinical models of autoimmune myositis and muscle atrophy.”
Reviewin preclinical models of autoimmune myositis and muscle atrophy
Cells